EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology

Ariana Sabzevari, Johnson Ung, Jeffrey W Craig, Kallesh D Jayappa, Ipsita Pal, David J Feith, Thomas P Loughran, Owen A O'Connor iD

CA: A Cancer Journal for Clinicians · 2025

DOI: 10.3322/caac.70001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, 2025. Verfasst von Ariana Sabzevari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology, and Cancer Biology, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Lymphoma, T-Cell, Peripheral, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FDA HHS, NCI NIH HHS, University of Virginia Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The peripheral T‐cell lymphomas (PTCL) are the only disease for which four histone deacetylase (HDAC) inhibitors have been approved globally as single agents. Although it is not clear why the PTCL exhibit such a vulnerability to these drugs, understanding the biological basis for this activity is essential. Many lines of data have established that the PTCL exhibit marked sensitivity to other epigenetically targeted drugs, including EZH2 and DNMT3 (DNA‐methyltransferase 3) inhibitors. Even more compelling is the finding that combinations of drugs targeting the epigenetic biology of PTCL are beginning to produce provocative data, leading some to wonder if these agents can replace historical chemotherapy regimens routinely used for patients with the disease. Simultaneously, the field has identified a spectrum of mutations in genes governing epigenetic biology in many subtypes of PTCL, although the T follicular helper lymphomas, including angioimmunoblastic T‐cell lymphoma, appear to be particularly enriched for these genetic features. While the direct relationship between the presence of any one of these mutations and responsiveness to a particular epigenetic drug has yet to be established, it is increasingly accepted that the PTCL may be the prototypical epigenetic disease as no other form of cancer has exhibited such a vulnerability to this diversity of epigenetically targeted agents. Herein, we comprehensively review this esoteric and rapidly evolving field to identify themes and lessons from these experiences that may guide efforts to improve outcomes of patients with T‐cell neoplasms. Furthermore, we will discuss how these concepts might be applied to the broader field of cancer medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epigenesis, GeneticLymphoma, T-Cell, PeripheralHistone Deacetylase InhibitorsHumansEnhancer of Zeste Homolog 2 ProteinAntineoplastic AgentsMutationMolecular Targeted Therapy

Stichwörter der Autor:innen

EZH2 and DNA‐methyltransferase 3 (DNMT3) inhibitorsepigeneticshistone deacetylase (HDAC)large granular lymphocyte (LGL) leukemia (LGLL)non‐Hodgkin lymphomaperipheral T‐cell lymphoma (PTCL)

Substanzen

Histone Deacetylase InhibitorsEnhancer of Zeste Homolog 2 ProteinAntineoplastic AgentsEZH2 protein, human

Autor:innen und Institutionen

  • Department of Microbiology, Immunology, and Cancer Biology, Charlottesville, Virginia, USA.
  • Department of Pathology, University of Virginia Medical Center, Charlottesville, Virginia, USA.
  • University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, USA.
  • Department of Medicine, Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.

ORCID-Profile: Owen A O'Connor

Förderung

  • FDA HHS
  • NCI NIH HHS
  • University of Virginia Cancer Center
  • American Cancer Society Research Professorship

Zitieren

APA

Sabzevari, A., Ung, J., Craig, J. W., Jayappa, K. D., Pal, I., Feith, D. J., Loughran, T. P., & O'Connor, O. A. (2025). Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.70001

Vancouver

Sabzevari A, Ung J, Craig JW, Jayappa KD, Pal I, Feith DJ, et al. Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology. CA: A Cancer Journal for Clinicians. 2025. doi:10.3322/caac.70001

BibTeX
@article{Sabzevari2025,
  author = {Sabzevari, Ariana and Ung, Johnson and Craig, Jeffrey W and Jayappa, Kallesh D and Pal, Ipsita and Feith, David J and Loughran, Thomas P and O'Connor, Owen A},
  title = {Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology},
  journal = {CA: A Cancer Journal for Clinicians},
  year = {2025},
  doi = {10.3322/caac.70001}
}
Kostenlos starten →